疗效我觉得如果说经典治疗上，其实前面这个药有目前成熟的钙神经磷酸酶抑制

Efficacy I think that if we talk about classic treatment, the previous drug actually has mature calcineurin inhibitors. In fact, many refractory patients have been treated with multi-target therapy, which means that calcineurin inhibitors have been added. Believumab is actually a drug that we are planning to use for patients who are ineffective even with multiple targets. Therefore, it is not easy to compare the effects of the two drugs on patients, because each has a response. Who do you think is more effective? Okay, or who is better than who else, I think belyumumab must be better in terms of recurrence rate, because this test has been observed for a very long time, and the indicators of recurrence have also been observed. The previous drug is not available, why ? Because the recurrence of calcineurin inhibitors is a common problem, the recurrence occurs after withdrawal, which is the characteristic of this medicine.

疗效我觉得如果说经典治疗上，其实前面这个药有目前成熟的钙神经磷酸酶抑制剂，其实很多难治的病人用了多靶点治疗，就是加上了钙神经磷酸酶抑制剂的，如果贝利尤单抗这个药其实我们现在是准备用在即使多靶点都无效的病人，所以两个药之间对病人的起效不好比较，因为各自都有应答，你说谁比谁更好，或者是谁比谁更优，我想在复发率上肯定是贝利尤单抗更优，因为这个试验观察的时间非常长，而且也观察了复发的指标，前面那个药就没有，为什么？因为钙神经磷酸酶抑制剂的复发是一个共性问题，撤药就复发，这是这个药的特点。

I think if we talk about the classical treatment, in fact, there are mature calcineurin inhibitors in the front of the drug. In fact, many refractory patients have been treated with multi-target therapy, that is, with the addition of calcineurin inhibitor. If baileyumab is actually used in patients who have no effect on multiple targets, the effect of the two drugs on patients will be improved It's not easy to compare, because each has its own response. You say who is better or who is better than whom. I think the relapse rate of baileyumab is definitely better, because the observation time of this experiment is very long, and the indicators of recurrence are also observed. Why? Because the recurrence of calcineurin inhibitors is a common problem, withdrawal of drugs on the recurrence, this is the characteristics of this drug.<br>